Published in Frontiers in Pharmacology
COSBI proudly announces the launch of stormTB, an innovative web-based simulator designed to model the pharmacokinetics of tuberculosis (TB) drugs using a minimal physiologically based pharmacokinetic (mPBPK) model in mice.
Developed in collaboration with the Gates Medical Research Institute, stormTB enables researchers to simulate and compare dosing regimens of 11 widely used anti-TB drugs. By providing a standardized platform, stormTB facilitates “what-if” analyses to accelerate the development of effective TB treatment strategies.
Accessible online and free to use, stormTB offers intuitive visualizations of drug concentration profiles, helping researchers better understand drug behavior and optimize therapeutic regimens before costly experimental trials.
We congratulate the COSBI authors — Roberto Visintainer, Anna Fochesato, Daniele Boaretti, Stefano Giampiccolo, Federico Reali, and Luca Marchetti — for their successful collaboration with the Gates Medical Research Institute in creating this powerful simulation platform.
This open-access tool highlights COSBI’s commitment to leveraging computational biology and systems pharmacology to tackle global health challenges. By empowering scientists worldwide with stormTB, COSBI aims to contribute to the fight against tuberculosis, a disease affecting millions globally.
Read the full article: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1462193/full
Explore the simulator and learn more at: https://apps.cosbi.eu/stormTB
